Study Findings on Type 2 Diabetes Are Outlined in Reports from University of Debrecen (Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 …)

Disease Prevention Daily

2021 FEB 05 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- New study results on type 2 diabetes have been published. According to news originating from Debrecen, Hungary, by NewsRx editors, the research stated, “Mortality and disability in diabetes mellitus are determined mostly by cardiovascular complications and cancer. The impact of dipeptidyl peptidase-4 inhibitor (DPP-4i) and sodium-glucose cotransporter-2 inhibitor (SGLT2i) monotherapy or combination on long-term complications of type 2 diabetes mellitus was studied.”

The news editors obtained a quote from the research from University of Debrecen: “Research design and methods Patients with type 2 diabetes treated with DPP-4i or SGLT2i during a 3-year period were identified in the database of the National Institute of Health Insurance Fund in Hungary. All-cause mortality, acute myocardial infarction, stroke, hospitalization for heart failure (HHF), lower limb amputation (LLA) and cancer were assessed. Outcomes of add-on SGLT2i to DPP-4i treatment in comparison with switching DPP-4i therapy to SGLT2i were also evaluated. After propensity score matching, survival analysis was performed with a Cox proportional hazards model. After propensity score matching, both SGLT2i and DPP-4i groups included 18 583 patients. All-cause mortality (HR, 0.80; 95% CI 0.68 to 0.94; p=0.0057), HHF (HR, 0.81; 95% CI 0.71 to 0.92; p=0.0018), and risk of cancer (HR, 0.75; 95% CI 0.66 to 0.86; p<0.0001) were lower in the SGLT2i population compared with DPP-4i. Risk of LLA was higher in the SGLT2i group (HR, 1.35; 95% CI 1.03 to 1.77; p=0.0315). SGLT2i in combination with DPP-4i results in lower all-cause mortality (HR, 0.46; 95% CI 0.31 to 0.67; p=0.0001), with a lower trend in stroke, LLA, HHF and cancer, but without any statistical difference.”

According to the news editors, the research concluded: “SGLT2i treatment leads to a lower risk of overall mortality, HHF and cancer when compared with DPP-4i treatment. Adding SGLT2i to DPP-4i instead of switching from DPP-4i to SGLT2i further lowers the risk of all-cause mortality.”

For more information on this research see: Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study. BMJ Open Diabetes Research & Care, 2021,9(1). (BMJ Open Diabetes Research & Care - http://drc.bmj.com/). The publisher for BMJ Open Diabetes Research & Care is BMJ Publishing Group.

A free version of this journal article is available at https://doi.org/10.1136/bmjdrc-2020-001765.

Our news journalists report that additional information may be obtained by contacting Zoltan Szekanecz, Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Additional authors for this research include Gyula Poor, Gabor Suto, Gergo A Molnar, Gyorgy Rokszin, Ibolya Fabian, Zoltan Kiss, Gyorgy Jermendy, Peter Kempler, Istvan Wittmann.